5 citations
,
March 2021 in “Hepatitis Monthly” This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.
5 citations
,
June 2019 in “Open Forum Infectious Diseases” This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.
2 citations
,
September 2021 in “International Journal of STD & AIDS” This study found that dermatoses are common in people living with HIV and may serve as indicators of disease stage, with certain conditions more prevalent when CD4+ counts are below 200/mm³.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.
December 2025 in “Molecular Pharmaceutics” In this study, researchers developed a coamorphous form of tadalafil and finasteride, showing improved solubility and dissolution in vitro, with results successfully translated in vivo in rats. They reported reasonable stability, suggesting this form could serve as a therapeutic alternative to the current marketed combination.